Get approval of Sacituzumab Govitecan (Trodelvy) for mTNBC for UK patients.

Rejected 12 signatures

What the petition asks

MHRA application for Trodelvy was made in January 2021, via Project Orbis, a system that the government promised would deliver rapid access to cutting edge cancer treatments, post Brexit. Trodelvy was approved by FDA in the USA, April 2020. Current timelines suggest UK patients will wait till 2022.

Of all the breast cancers, metastatic Triple Negative Breast Cancer (mTNBC) is the hardest to treat with the worst prognosis. The average life expectancy is 12-18 months. Trodelvy can work to shrink cancer in patients who are otherwise resistant to chemotherapy. In the UK every year, around 1650 women die of metastatic TNBC, post co-vid these figures are likely to be double.

Why it was rejected

It asked for something that is not the responsibility of the UK Government or Parliament.

We can't accept your petition because the UK Government and Parliament aren't responsible for the issue you raise.

Decisions about which medicines can be offered to patients on the NHS are made by the Medicines and Healthcare Products Regulatory Authority and the National Institute for Health and Care Excellence. Both of these bodies are operationally independent of the UK Government and Parliament.

Timeline

17 Jul 2021	Petition opened for signatures
21 Jul 2021	Rejected by the Petitions Committee

Key facts

Signatures 12

Status Rejected

Rejected 21 Jul 2021

Follow this petition